- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00887822
A Study of Bevacizumab (Avastin) Versus Placebo in Combination With Capecitabine (Xeloda) and Cisplatin as First-Line Therapy for Advanced Gastric Cancer (AVATAR)
10 gennaio 2017 aggiornato da: Hoffmann-La Roche
A Double-Blind, Randomized, Multicenter, Phase III Study of Bevacizumab in Combination With Capecitabine and Cisplatin Versus Placebo in Combination With Capecitabine and Cisplatin, as First-Line Therapy in Patients With Advanced Gastric Cancer.
This 2 arm study will compare the efficacy and safety of bevacizumab in combination with capecitabine and cisplatin versus placebo in combination with capecitabine and cisplatin in participants who have not received prior chemotherapy for advanced or metastatic gastric cancer.
Participants will be randomized to one of two treatment groups Bevacizumab + Capecitabine/Cisplatin (experimental arm) or Placebo + Capecitabine/Cisplatin (control arm).
Panoramica dello studio
Stato
Completato
Condizioni
Intervento / Trattamento
Tipo di studio
Interventistico
Iscrizione (Effettivo)
202
Fase
- Fase 3
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Beijing, Cina, 100021
-
Beijing, Cina, 100142
-
Beijing, Cina, 100071
-
Beijing, Cina, 100853
-
ChongQing, Cina, 400042
-
Guangzhou, Cina, 510060
-
Hangzhou, Cina, 310016
-
Nanjing, Cina
-
Nanjing, Cina, 210036
-
Shanghai, Cina, 200032
-
Shanghai, Cina, 200080
-
Shantou, Cina, 515041
-
Shenyang, Cina, 110001
-
Wuhan, Cina, 430030
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Descrizione
Inclusion Criteria:
- Histologically confirmed adenocarcinoma of the stomach or gastro-oesophageal junction with inoperable, locally advanced or metastatic disease, not amenable to curative therapy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2
- Measurable disease or non-measurable but evaluable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)
Exclusion Criteria:
- Previous chemotherapy for locally advanced or metastatic gastric cancer
- Previous platinum or anti-angiogenic therapy
- Radiotherapy within 28 days of randomization
- Evidence of Central Nervous System (CNS) metastasis at baseline
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Bevacizumab, Capecitabine and Cisplatin
Participants will receive bevacizumab 7.5 milligrams per kilogram (mg/kg) intravenous (IV) infusion on Day 1 of every 3-week cycle in combination with capecitabine 1000 milligrams per square meter (mg/m^2) orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
|
7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
Altri nomi:
1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
Altri nomi:
80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
|
|
Comparatore placebo: Placebo, Capecitabine and Cisplatin
Participants will receive placebo matched to bevacizumab on Day 1 of every 3-week cycle in combination with capecitabine 1000 mg/m^2 orally twice daily (total daily dose 2000 mg/m^2) on Days 1-14 of every 3-week cycle and cisplatin 80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles; until disease progression or unmanageable toxicity.
|
1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
Altri nomi:
80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
Placebo matched to bevacizumab on Day 1 of every 3-week cycle
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants With Event (Death)
Lasso di tempo: From randomization until death (up to 34 months)
|
Percentage of participants who died due to any cause was reported.
As planned, ad hoc analysis was done for overall survival up to clinical cut-off date of 12 January 2012 (34 months), subsequent to the protocol-defined clinical cut-off date of 13 May 2011 (26 months).
Overall survival was defined as the time between randomization and the date of death due to any cause.
|
From randomization until death (up to 34 months)
|
|
Overall Survival
Lasso di tempo: From randomization until death (up to 34 months)
|
Overall survival was defined as the time between randomization and the date of death due to any cause.
Overall survival was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants for whom no death was captured on the clinical database were censored at the most recent date they were known to be alive.
As planned, ad hoc analysis was done for overall survival up to clinical clinical cut-off date of 12 January 2012 (34 months), subsequent to the protocol-defined clinical cut-off date of 13 May 2011 (26 months).
|
From randomization until death (up to 34 months)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants With Progression-Free Survival (PFS) Events (Disease Progression/Death)
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20 percent (%) increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 millimeters (mm), progression of existing non-target lesions, or presence of new lesions.
PFS was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first, according to Response Evaluation Criteria In Solid Tumors (RECIST).
|
From randomization until disease progression or death (up to 26 months)
|
|
Progression-Free Survival (PFS)
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
PFS was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first, according to RECIST.
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who had neither progressed nor died at the time of study completion or who were lost to follow-up were censored at the date of the last tumor assessment or last follow-up for progression of disease.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With PFS Events (Disease Progression/Death) During First-line Therapy
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS during first-line therapy was defined as the time between randomization and the date of first documented disease progression or death, whichever occurred first and only if it occurred no later than 28 days after last confirmed intake of any study medication and before the start of non-study antineoplastic treatment, according to RECIST.
|
From randomization until disease progression or death (up to 26 months)
|
|
PFS During First-line Therapy
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
PFS during first-line therapy was defined as time between randomization and date of first documented disease progression or death, whichever occurred first and only if it occurred no later than 28 days after last intake of any study medication and only if it occurred before start of non-study antineoplastic treatment, according to RECIST.
Progression of disease was defined as at least 20% increase in sum of longest diameters of target lesions compared to smallest sum of longest diameters on-study & absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who neither progressed nor died in this interval, or who were lost to follow-up were censored at date of last tumor assessment/last follow-up within this time window.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Disease Progression
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
|
From randomization until disease progression or death (up to 26 months)
|
|
Time to Progression
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
Time to progression was defined as the time between randomization and the first occurrence of disease progression.
Progression of disease was defined as at least 20% increase in the sum of longest diameters of target lesions compared to the smallest sum of longest diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
Time to progression was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who had not progressed at the time of study completion (including participants who had died before disease progression) or who were lost to follow-up were censored at the date of the last tumor assessment or last follow-up for progression of disease.
Participants for whom no post-baseline tumor assessments were available were censored at day of randomization.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Best Overall Response as Assessed by RECIST During First-Line Therapy
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
Best overall response during first-line therapy was defined as the occurrence of either a confirmed complete (CR) or a partial response (PR), as assessed by the RECIST criteria.
CR: disappearance of all target and non-target lesions (TLs) and normalization of tumor markers.
Pathological lymph nodes must have short axis measures less than (<) 10 mm.
PR: at least a 30 % decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of longest diameters.
|
From randomization until disease progression or death (up to 26 months)
|
|
Duration of Response During First-Line Therapy
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
Duration of response during first-line therapy was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death (whichever occurs first) during first-line therapy.
CR: disappearance of all target and non-TLs and normalization of tumor markers.
Pathological lymph nodes must have short axis measures <10 mm.
PR: at least a 30 % decrease in the sum of measures (longest diameter for tumor lesions and short axis measure for nodes) of TLs, taking as reference the baseline sum of longest diameters.
Duration of response was estimated using Kaplan Meier method.
Reported data included censored observations.
Participants who did not progress or die after they had had a confirmed response were censored at the date of their last tumor measurement or last follow-up for progression of disease during first line therapy.
|
From randomization until disease progression or death (up to 26 months)
|
|
Percentage of Participants With Disease Control During First-Line Therapy
Lasso di tempo: From randomization until disease progression or death (up to 26 months)
|
Disease control was defined as stable disease(SD) for 6 weeks or longer, CR plus PR as assessed by RECIST criteria for participants with measurable disease.CR:disappearance of all TLs & normalization of tumor markers.
Pathological lymph nodes must have short axis measures<10 mm.
PR:at least 30% decrease in sum of measures(longest diameter for tumor lesions and short axis measure for nodes)of TLs, taking as reference baseline sum of longest diameters.SD:neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression taking as reference smallest sum of longest diameters on study.
For participants without measurable disease, clinical benefit rate was defined as no clinical disease progression for >/=6 weeks.
Disease progression was defined as at least 20% increase in sum of diameters of TLs compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
|
From randomization until disease progression or death (up to 26 months)
|
|
Change From Cycle 1 in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 36 (QLQ-C30) Scale Over Time
Lasso di tempo: From Cycle 1 until disease progression (up to 26 months)
|
EORTC QLQ-C30 included global health status (GHS)/quality of life (QOL), functional scales (physical, role, cognitive, emotional, and social), symptom scales (fatigue, pain, nausea/vomiting), and single items (dyspnea, appetite loss, insomnia, constipation, diarrhea, and financial difficulties).
Most questions used a 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used a 7-point scale (1 'Very Poor' to 7 'Excellent').
Scores were averaged and transformed to 0-100 scale; a higher score for Global Qol/functional scales=better level of QoL/functioning, or a higher score for symptom scale=greater degree of symptoms.
|
From Cycle 1 until disease progression (up to 26 months)
|
|
Change From Cycle 1 in EORTC QLQ-STO22 Scale Over Time
Lasso di tempo: From Cycle 1 until disease progression (up to 26 months)
|
The EORTC QLQ-STO22 is a gastric cancer quality of life questionnaire.
There are 22 questions which comprise 5 scales (dysphagia, pain, reflux symptom, dietary restrictions, and anxiety) and 4 single items (dry mouth, hair loss, taste, body image).
Most questions used 4-point scale (1 'Not at all' to 4 'Very much'; 1 question was a yes or no answer).
A linear transformation was used to standardize all scores and single-items to a scale of 0 to 100; higher score=better level of functioning or greater degree of symptoms.
|
From Cycle 1 until disease progression (up to 26 months)
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 marzo 2009
Completamento primario (Effettivo)
1 maggio 2011
Completamento dello studio (Effettivo)
1 agosto 2014
Date di iscrizione allo studio
Primo inviato
22 aprile 2009
Primo inviato che soddisfa i criteri di controllo qualità
23 aprile 2009
Primo Inserito (Stima)
24 aprile 2009
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
1 marzo 2017
Ultimo aggiornamento inviato che soddisfa i criteri QC
10 gennaio 2017
Ultimo verificato
1 gennaio 2017
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie dell'apparato digerente
- Neoplasie
- Neoplasie per sede
- Neoplasie gastrointestinali
- Neoplasie dell'apparato digerente
- Malattie gastrointestinali
- Malattie dello stomaco
- Neoplasie allo stomaco
- Effetti fisiologici delle droghe
- Meccanismi molecolari dell'azione farmacologica
- Antimetaboliti, Antineoplastici
- Antimetaboliti
- Agenti antineoplastici
- Agenti antineoplastici, immunologici
- Inibitori dell'angiogenesi
- Agenti di modulazione dell'angiogenesi
- Sostanze per la crescita
- Inibitori della crescita
- Cisplatino
- Capecitabina
- Bevacizumab
Altri numeri di identificazione dello studio
- ML22367
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .